Skip to content
Menu

Citigroup Maintains Buy on SpyGlass Pharma, Raises Price Target to $45

Benzinga Newsdesk 3 days ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Citigroup analyst Yigal Nochomovitz maintains SpyGlass Pharma (NASDAQ:SGP) with a Buy and raises the price target from $42 to $45.

Citigroup analyst Yigal Nochomovitz maintains SpyGlass Pharma (NASDAQ:SGP) with a Buy and raises the price target from $42 to $45.

Read at benzinga.com